DK1851236T3 - Makrolider med anti-inflammaterisk virkning - Google Patents

Makrolider med anti-inflammaterisk virkning

Info

Publication number
DK1851236T3
DK1851236T3 DK06727595.8T DK06727595T DK1851236T3 DK 1851236 T3 DK1851236 T3 DK 1851236T3 DK 06727595 T DK06727595 T DK 06727595T DK 1851236 T3 DK1851236 T3 DK 1851236T3
Authority
DK
Denmark
Prior art keywords
macrolides
excessive
relates
activity
inflammatory action
Prior art date
Application number
DK06727595.8T
Other languages
Danish (da)
English (en)
Inventor
Ognjen Culic
Martina Bosnar
Nikola Marjanovic
Dubravko Jelic
Sulejman Alihodzic
Vanja Vela
Zorica Marusic-Istuk
Vesna Erakovic
Berislav Bosnjak
Boska Hrvacic
Marija Tomaskovic
Vesna Munic
Vanesa Ivetic
Antun Hutinec
Goran Kragol
Marija Leljak
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1851236T3 publication Critical patent/DK1851236T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06727595.8T 2005-01-13 2006-01-13 Makrolider med anti-inflammaterisk virkning DK1851236T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64384105P 2005-01-13 2005-01-13
US71582805P 2005-09-09 2005-09-09
PCT/IB2006/001238 WO2006087644A2 (en) 2005-01-13 2006-01-13 Macrolides with anti-inflammatory activity

Publications (1)

Publication Number Publication Date
DK1851236T3 true DK1851236T3 (da) 2010-11-22

Family

ID=36916830

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06727595.8T DK1851236T3 (da) 2005-01-13 2006-01-13 Makrolider med anti-inflammaterisk virkning

Country Status (18)

Country Link
US (2) US8080529B2 (https=)
EP (1) EP1851236B1 (https=)
JP (1) JP5036558B2 (https=)
KR (1) KR20070105993A (https=)
CN (1) CN101142225B (https=)
AT (1) ATE476438T1 (https=)
AU (1) AU2006215315B2 (https=)
CA (1) CA2594820A1 (https=)
CY (1) CY1110866T1 (https=)
DE (1) DE602006015919D1 (https=)
DK (1) DK1851236T3 (https=)
HR (1) HRP20100549T1 (https=)
IL (1) IL184438A (https=)
NO (1) NO20074162L (https=)
PL (1) PL1851236T3 (https=)
PT (1) PT1851236E (https=)
RS (1) RS51479B (https=)
WO (1) WO2006087644A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271656A1 (en) * 2008-04-23 2011-01-12 Glaxo Group Limited 2'-o,3'-n-bridged macrolides
CN101423539B (zh) * 2008-12-09 2011-04-27 山东大学 4″,11-二氨基甲酸酯阿奇霉素衍生物、制备方法及其药物组合物
CN102378763A (zh) * 2009-01-30 2012-03-14 葛兰素集团有限公司 消炎的大环内酯
ES2582794T3 (es) 2009-08-13 2016-09-15 Basilea Pharmaceutica Ag Nuevos macrólidos y su uso
WO2011131749A1 (en) 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
JP6437523B2 (ja) 2013-04-04 2018-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ マクロライドならびにそれらの調製および使用の方法
US20160031925A1 (en) 2013-04-10 2016-02-04 Probiotic Pharmaceuticals Aps Azithromycin antimicrobial derivatives with non-antibiotic pharmaceutical effect
CN106998685A (zh) * 2014-10-08 2017-08-01 哈佛大学的校长及成员们 14‑元酮内酯及其制备和使用方法
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
GB201520419D0 (en) 2015-11-19 2016-01-06 Epi Endo Pharmaceuticals Ehf Compounds
TWI830987B (zh) * 2020-03-12 2024-02-01 美商碩騰服務公司 免疫調節脲氮雜內酯
WO2022128054A1 (en) 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammatory conditions of human skin (iv)
CN114858953B (zh) * 2022-05-20 2023-11-21 大连工业大学 一种动物源食品中红霉素及降解产物的检测试剂盒及检测方法
GB202404587D0 (en) 2024-03-28 2024-05-15 Epiendo Pharmaceuticals Ehf Chemical forms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126344A2 (en) * 1983-05-20 1984-11-28 Abbott Laboratories Tripeptide esters of therapeutic agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
HRP980189B1 (en) 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
RS20050008A (sr) * 2002-07-08 2007-06-04 Pliva-Istraživački Institut D.O.O., Nova jedinjenja,kompozicije i metode za lečenje inflamatornih oboljenja i stanja
GB0310986D0 (en) * 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
DE602006004555D1 (de) 2005-01-13 2009-02-12 Glaxosmithkline Zagreb Decladinosyl-macrolide mit entzündungshemmender wirkung
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
CN102378763A (zh) 2009-01-30 2012-03-14 葛兰素集团有限公司 消炎的大环内酯

Also Published As

Publication number Publication date
DE602006015919D1 (de) 2010-09-16
CN101142225A (zh) 2008-03-12
CY1110866T1 (el) 2015-06-10
WO2006087644A3 (en) 2007-03-15
PL1851236T3 (pl) 2011-05-31
JP2008526950A (ja) 2008-07-24
AU2006215315B2 (en) 2012-02-16
IL184438A (en) 2011-12-29
HRP20100549T1 (hr) 2010-11-30
EP1851236B1 (en) 2010-08-04
HK1112920A1 (en) 2008-09-19
US20120058963A1 (en) 2012-03-08
KR20070105993A (ko) 2007-10-31
US20080221046A1 (en) 2008-09-11
JP5036558B2 (ja) 2012-09-26
NO20074162L (no) 2007-09-18
ATE476438T1 (de) 2010-08-15
CN101142225B (zh) 2011-09-07
AU2006215315A1 (en) 2006-08-24
PT1851236E (pt) 2010-10-25
EP1851236A2 (en) 2007-11-07
WO2006087644A2 (en) 2006-08-24
RS51479B (sr) 2011-04-30
US8080529B2 (en) 2011-12-20
CA2594820A1 (en) 2006-08-24
IL184438A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
IL184438A0 (en) Macrolides with anti-inflammatory activity
ATE549338T1 (de) Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
EA200900136A1 (ru) Пирролопиримидины для фармацевтических композиций
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
GEP20115302B (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5- trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
DE602005027707D1 (de) Isoindolin-verbindungen und deren verwendungen
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
NO20081050L (no) Kaspaseinhibitor-prodroger
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE453642T1 (de) Substituierte phenylaminopyrimidine
CR9183A (es) Tiazolidinonas metasustituidas, su preparacion y su uso como medicamento
EA200601462A1 (ru) Соединения для лечения заболеваний
DE602006004555D1 (de) Decladinosyl-macrolide mit entzündungshemmender wirkung
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
AR054779A1 (es) N-(2,2-dimetilpropil)-6-{3-fluoro-5-[(3-isoxazolilamino)carbonil]-2-metilfenil}-3-piridinacarboxamida
ATE427315T1 (de) Neue makrolide
EP1841420A4 (en) TREATMENT OF REMEDIENT-RESISTANT PROLIFERATIVE DISEASES
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
ATE471318T1 (de) Neue indol-pyrrol-derivate zur behandlung proliferativer und inflammatorischer krankheiten
CL2007000955A1 (es) Compuesto peptidico lantibiotico con actividad antimicrobiana obtenido de un cultivo de bacillus clausii; procedimiento de preparacion; composicion famrceutica que lo comprende; y uso del compuesto peptidico para tratar trastornos intestinales producto de enfermedades infecciosas.
EA200701835A1 (ru) Амидные производные в качестве лигандов ионных каналов, их фармацевтические композиции и способы их применения
ATE435868T1 (de) Homogemcitabine